 SNPX did not achieve primary endpoints in two Phase 2 studies for Bryostatin for the treatment of Alzheimers Disease in moderately severe to severe patients. Post-hoc analysis of 95 patients from these two studies with MMSE 10-15, and not taking Namenda, revealed a statistically significant improvement vs placebo. 